Welcome to our dedicated page for Immunitybio SEC filings (Ticker: IBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmunityBio, Inc. filings document the formal reporting record for a commercial-stage immunotherapy company with Nasdaq-listed common stock. Form 8-K reports furnish operating results, ANKTIVA product revenue updates, regulatory authorizations for ANKTIVA with BCG in NMIBC, FDA promotional-compliance correspondence, and material agreements including revenue interest purchase agreement amendments and convertible promissory note amendments.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data, and shareholder voting matters. The filings also describe capital structure and financing obligations, related-party arrangements, and risk factors tied to clinical development, regulatory review, manufacturing and supply, commercialization, reimbursement, competition, and market acceptance.
ImmunityBio director Barry J. Simon reported an open-market sale of common stock. On this Form 4, he sold 75,000 shares of ImmunityBio, Inc. common stock in an open-market transaction at a weighted average price of $12.0105 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2024. After this sale, Simon directly holds 2,850,821 shares of ImmunityBio common stock, according to the filing.
ImmunityBio, Inc. received an updated ownership report showing that Dr. Patrick Soon‑Shiong and affiliated entities beneficially own about 745,576,456 shares of common stock, or 66.3% of the company. This total includes his direct holdings, stock options, restricted stock units, and multiple investment vehicles and a family foundation.
Key entities linked to this stake include Cambridge Equities, LP with 261,705,814 shares (25.5%), Nant Capital, LLC with 339,465,529 shares (30.3%), California Capital Equity, LLC with 106,511,412 shares (10.4%), and NantWorks, LLC with 98,535,253 shares (9.6%). Percentages are calculated using 1,028,111,456 shares outstanding as of February 19, 2026, plus additional shares Dr. Soon‑Shiong and Nant Capital may acquire within 60 days.
ImmunityBio, Inc. director Christobel Selecky reported an option exercise and share sale. On February 23, 2026, she exercised a stock option for 25,000 shares, acquiring an equal number of ImmunityBio common shares at a price of $2.98 per share through the derivative conversion. A related option line shows 25,000 stock option rights exercised, with 67,937 options remaining directly owned after the transaction. On the same date, she then sold 25,000 common shares at $10.00 per share, leaving 0 shares from that lot directly owned after the sale. The sale was carried out under a Rule 10b5-1 trading plan adopted on June 12, 2025, and all shares underlying the option had fully vested on June 12, 2023.
ImmunityBio, Inc. Chief Financial Officer David C. Sachs reported the vesting and settlement of restricted stock units. On February 22, 2026, 40,650 RSUs were exercised into the same number of common shares at $0.00 per share. To cover tax withholding, 20,682 common shares were automatically disposed of at $8.70 per share, a price based on the February 20, 2026 closing price. After these transactions, Sachs directly held 300,143 shares of common stock and 40,651 restricted stock units, reflecting routine equity compensation vesting rather than an open‑market trade.
ImmunityBio director and major holder Patrick Soon-Shiong reported vesting of restricted stock units and related share movements. On February 22, 2026, 114,329 restricted stock units were exercised into an equal number of common shares at $0.00 per share. To cover tax obligations, 58,170 common shares were disposed of at $8.70 per share through share withholding, leaving 29,757,911 common shares held directly after these transactions. Additional large blocks of ImmunityBio common stock are reported as held indirectly through affiliated entities such as Nant Capital, Cambridge Equities, NantBio, California Capital Equity, the Chan Soon-Shiong Family Foundation, NantWorks, NantMobile, and NantCancerStemCell, over which the reporting person may be deemed to have voting and dispositive power as described in the footnotes.
ImmunityBio, Inc. Chief Accounting Officer Regan J. Lauer reported vesting of 4,065 restricted stock units (RSUs) on February 22, 2026. Each RSU converts into one share of common stock, so 4,065 shares were acquired at a stated price of $0.00 per share.
To satisfy tax obligations from this vesting, 1,673 common shares were disposed of at $8.70 per share through share withholding, rather than an open-market sale. After these transactions, Lauer directly owns 115,875 shares of ImmunityBio common stock.
ImmunityBio, Inc. director, CEO and President Richard Adcock reported equity award activity involving restricted stock units (RSUs) and common stock. On February 22, 2026, 152,439 RSUs were exercised or converted into 152,439 shares of common stock at a price of $0.00 per share, reflecting vesting of a prior RSU grant.
In a related tax-withholding transaction, 77,560 shares of common stock were disposed of at $8.70 per share to cover tax obligations associated with the RSU vesting, rather than an open-market sale. Following these transactions, Adcock directly held 560,344 shares of ImmunityBio common stock. Footnotes explain that each RSU represents a right to receive one share of common stock and outline a three-year vesting schedule that began on February 22, 2024, conditioned on continued service.
ImmunityBio director Barry J. Simon reported a mix of stock sales and equity awards for ImmunityBio, Inc. common stock. He sold 165,000 shares on February 23, 2026 in open-market transactions at a weighted average price of $10.2491 per share under a Rule 10b5-1 trading plan, and sold another 10,000 shares on February 20, 2026 at $9.25 per share. On February 22, 2026, restricted stock units representing 15,243 shares vested and were converted into common stock at no cost, with 6,026 shares withheld at $8.70 per share to cover taxes. After these transactions, he directly owned 2,925,821 shares of ImmunityBio common stock.
ImmunityBio, Inc. outlines how it is transitioning into a commercial-stage immunotherapy company built around its IL-15 receptor superagonist ANKTIVA. Net product revenue reached approximately $113 million in 2025, with about 700% year-over-year growth and Q4 2025 revenue of $38.3 million, supported by lives covered exceeding 240 million in the U.S.
ANKTIVA with BCG is approved for BCG-unresponsive NMIBC CIS in the U.S., UK and Saudi Arabia and has conditional EU authorization, while Saudi Arabia granted conditional approval with checkpoint inhibitors for metastatic NSCLC. The company is running an extensive pipeline of trials across bladder, lung, pancreatic, brain and hematologic cancers, as well as infectious diseases, and has received FDA RMAT designation and multiple expanded access authorizations tied to lymphopenia reversal.
ImmunityBio, Inc. outlines how it is transitioning into a commercial-stage immunotherapy company built around its IL-15 receptor superagonist ANKTIVA. Net product revenue reached approximately $113 million in 2025, with about 700% year-over-year growth and Q4 2025 revenue of $38.3 million, supported by lives covered exceeding 240 million in the U.S.
ANKTIVA with BCG is approved for BCG-unresponsive NMIBC CIS in the U.S., UK and Saudi Arabia and has conditional EU authorization, while Saudi Arabia granted conditional approval with checkpoint inhibitors for metastatic NSCLC. The company is running an extensive pipeline of trials across bladder, lung, pancreatic, brain and hematologic cancers, as well as infectious diseases, and has received FDA RMAT designation and multiple expanded access authorizations tied to lymphopenia reversal.
ImmunityBio, Inc. notice: a Form 144 discloses a proposed sale of 25,000 common shares on 02/23/2026 related to an exercise of stock options. The filing records prior 10b5-1 sales by Christobel Selecky of 25,000 shares on 01/20/2026 for $187,650 and 50,000 shares on 01/16/2026 for $250,000.
ImmunityBio, Inc. notice: a Form 144 discloses a proposed sale of 25,000 common shares on 02/23/2026 related to an exercise of stock options. The filing records prior 10b5-1 sales by Christobel Selecky of 25,000 shares on 01/20/2026 for $187,650 and 50,000 shares on 01/16/2026 for $250,000.